Chris Howerton
Stock Analyst at Jefferies
(2.48)
# 2,321
Out of 4,876 analysts
74
Total ratings
42.37%
Success rate
13.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $3.69 | +117.10% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $21.08 | +274.76% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.94 | +106.19% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.66 | +52.60% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.03 | +17,239.90% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $4.76 | +15,026.05% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.63 | -69.33% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $13.11 | -23.72% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.63 | -23.95% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $9.29 | +18.47% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $18.40 | +117.39% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $31.86 | +91.46% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $102.57 | -12.26% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.82 | +148.96% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.22 | +10,227.87% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.48 | +1,251.35% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $21.17 | +211.76% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.03 | +337.38% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.48 | +1,318.92% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.14 | +1,829.82% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.31 | +1,662.45% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.21 | -5.45% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $9.51 | +5,998.84% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.17 | +5,028.21% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $74.33 | -78.47% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $55.22 | -51.10% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $13.38 | +8,868.61% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $3.69
Upside: +117.10%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $21.08
Upside: +274.76%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.94
Upside: +106.19%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.66
Upside: +52.60%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.03
Upside: +17,239.90%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $4.76
Upside: +15,026.05%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.63
Upside: -69.33%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $13.11
Upside: -23.72%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.63
Upside: -23.95%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $9.29
Upside: +18.47%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $18.40
Upside: +117.39%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $31.86
Upside: +91.46%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $102.57
Upside: -12.26%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.82
Upside: +148.96%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.22
Upside: +10,227.87%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.48
Upside: +1,251.35%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $21.17
Upside: +211.76%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.03
Upside: +337.38%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.48
Upside: +1,318.92%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.14
Upside: +1,829.82%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.31
Upside: +1,662.45%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.21
Upside: -5.45%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $9.51
Upside: +5,998.84%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.17
Upside: +5,028.21%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $74.33
Upside: -78.47%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $55.22
Upside: -51.10%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $13.38
Upside: +8,868.61%